Pharmacokinetic (PK) and Pharmacodynamic (PD) Modeling of Ampicillin and Gentamicin in Peripartum Patients
Study Details
Study Description
Brief Summary
This study proposes to compare the metabolism of Ampicillin and Gentamicin by pregnant women to that of non-pregnant women; the placental transfer over time; and the subsequent metabolism of the transferred drug(s) in the neonate.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Pregnant women who present to Labor and Delivery will be identified as potential participants based on Inclusion/Exclusion criteria and their need to receive Ampicillin and/or Gentamicin therapy. The additional group of 20 non-pregnant women will also be identified based on Inclusion/Exclusion criteria and their need to receive Ampicillin and/or Gentamicin therapy.
Once identified, interested candidates will be fully informed of the study procedures, have all questions answered, and informed consent obtained.
Pregnant participants will receive Ampicillin 2g IV loading dose followed by 1g IV every 4 hrs until delivery; or Ampicillin 2g IV every 6hrs along with Gentamicin 5mg/kg IV every 24 hrs. Dose times will be recorded.
Non-pregnant participants will receive similar doses of either Ampicillin and/or Gentamicin, if not the same dose(s).
Fingerstick blood collection will be drawn from both populations at the following timepoints:
-
before the administration of Ampicillin, and/or
-
before the administration of Gentamicin
-
after the full initial dose of the antibiotic has infused, at 5 min, 15 min, 30 min, 2-3hr, 4-6hr, immediately prior to the next dose of drug, and at DELIVERY (a 5 minute window for each timepoint will be permitted) If delivery occurs prior to the 3 or 6 hr timepoints, fingerstick blood collection should continue
Samples will be obtained on filter paper via the Dry Blood Spot (DBS) method, which is clinically appropriate for the purposes of this study.
Umbilical venous and arterial blood will also be drawn for sampling from the placenta after delivery, and cutting of the umbilical cord.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Pregnant/Ampicillin pregnant participants who will receive Ampicillin for conditions such as Group B Streptococcus |
Drug: Ampicillin
Pregnant participants will receive Ampicillin 2g IV loading dose followed by 1g IV every 4 hrs until delivery for Group B Strep prophylaxis; non-pregnant participants will receive Ampicillin for qualifying diagnosis
|
| Non-pregnant/Ampicillin non-pregnant participants who will receive Ampicillin for a qualifying hospital admission |
Drug: Ampicillin
Pregnant participants will receive Ampicillin 2g IV loading dose followed by 1g IV every 4 hrs until delivery for Group B Strep prophylaxis; non-pregnant participants will receive Ampicillin for qualifying diagnosis
|
| Pregnant and Non-pregnant/Ampicillin and Gentamicin pregnant participants who will receive Ampicillin and Gentamicin for conditions such as chorioamnionitis; non-pregnant participants who will receive Ampicillin and Gentamicin for a qualifying hospital admission |
Drug: Ampicillin and Gentamicin
Pregnant participants will receive Ampicillin 2g IV every 6hrs along with Gentamicin 5mg/kg IV every 24 hrs for chorioamnionitis; non-pregnant participants will receive for qualifying diagnosis
|
| Non-Pregnant/Gentamicin non-pregnant participants who will receive Gentamicin for a qualifying hospital admission |
Drug: Gentamicin
Prescribed to non-pregnant participants
|
Outcome Measures
Primary Outcome Measures
- Pharmacokinetic Profiling to Measure Maternal Metabolism of Ampicillin and/or Gentamicin in Pregnancy [predose; after the full initial dose of the antibiotic has infused, at 5min, 15min, 30min, 2-3hr, 4-6hr, immediately prior to the next dose of drug, and at DELIVERY]
blood samples will be taken at the above timepoints; data analysis of all specimens will begin approx. 12-15 months from start of study
Secondary Outcome Measures
- Profile of Neonatal Metabolism of Ampicillin and Gentamicin That Crosses the Placental Barrier [At delivery/upon cutting of umbilical cord]
blood samples to be drawn at the above timepoint; data analysis of all specimens will begin approx. 12-15 months from start of study
- PD Modeling of Peripartum Patients Receiving Ampicillin and/or Gentamicin [predose; while dosing; post dose]
subject will be observed for adverse events related to drug administration
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Generally healthy, pregnant woman (28-42 weeks)
-
Generally healthy, non-pregnant female
-
Scheduled to receive Ampicillin and/or Gentamicin IV
-
Ages 18-55 years old
-
Relatively normal Comprehensive Metabolic Panel (if available), as evidenced by recent blood work
-
Able and willing to sign consent
Exclusion Criteria:
-
Women with known renal or hepatic impairment; preeclampsia; Diabetes, including Gestational; any medical condition that, in the opinion of the Investigator or research team member, could potentially interfere with the study objectives
-
Women who are participating in another study
-
Pregnant with multiples
-
BMI > 40
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Lucille Packard Children's Hospital | Palo Alto | California | United States | 94304 |
Sponsors and Collaborators
- Stanford University
- David Drover, MD
Investigators
- Study Director: Brendan Carvalho, MBBCh, Stanford University
- Study Director: David Drover, MD, Stanford University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 29664